l)ethanone and ethyl 1-benzyl-2-methyl-5-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)-1H-indole-3-carboxylate derivatives were designed based on bioisosteric replacement of previously reported antitubercular agent (IND-07). Twenty ligands were successfully synthesized and some of them were found to have good in vitro activity (MIC < 10 μM) against the H37Rv strain of Mycobacterium tuberculosis. Among
一系列1-(1-苄基-2-甲基-5-((1-苯基-
1H-1,2,3-三唑-4-基)甲氧基)-1H-
吲哚-3-基)乙酮和乙基1-苄基-2-甲基-5-(((1-苯基-
1H-1,2,3-三唑-4-基)甲氧基)-1H-
吲哚-3-
羧酸酯衍
生物是基于先前报道的
生物立体替代方法设计的抗结核药(IND-07)。成功合成了20个
配体,其中一些对结核分枝杆菌H37Rv株具有良好的体外活性(MIC <10μM)。在这些化合物中,KC-08和KC-11抑制Mtb-DHFR的选择性分别是Ht-DHFR的4倍和18倍。与IND-07相比,化合物KC-11显示出可接受的A
DME和更好的药代动力学特征。进行对接研究以预测化合物在Mtb-DHFR和h-DHFR活性位点内的结合模式。